Prime Medicine (PRME) Stock Forecast, Price Target & Predictions
PRME Stock Forecast
Prime Medicine stock forecast is as follows: an average price target of $17.25 (represents a 335.61% upside from PRME’s last price of $3.96) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
PRME Price Target
PRME Analyst Ratings
Prime Medicine Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 07, 2024 | Maury Raycroft | Jefferies | $15.00 | $5.40 | 177.78% | 278.79% |
Apr 02, 2024 | David Nierengarten | Wedbush | $12.00 | $6.32 | 89.87% | 203.03% |
Oct 09, 2023 | Kostas Biliouris | BMO Capital | $19.00 | $8.75 | 117.14% | 379.80% |
Nov 14, 2022 | - | Morgan Stanley | $23.00 | $21.12 | 8.90% | 480.81% |
Prime Medicine Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $13.50 |
Last Closing Price | $3.96 | $3.96 | $3.96 |
Upside/Downside | -100.00% | -100.00% | 240.91% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 01, 2024 | BMO Capital | Outperform | Outperform | Hold |
May 20, 2024 | H.C. Wainwright | - | Buy | Initialise |
May 15, 2024 | Citigroup | - | Buy | Upgrade |
Apr 08, 2024 | Cowen & Co. | - | Buy | Initialise |
Apr 03, 2024 | Wedbush | Buy | Outperform | Initialise |
Apr 02, 2024 | Wedbush | - | Buy | Initialise |
Nov 14, 2022 | Morgan Stanley | - | Equal-Weight | Initialise |
Prime Medicine Financial Forecast
Prime Medicine Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $25.53M | $27.44M | $29.48M | $31.68M | $6.63M | $7.09M | $1.63M | $1.92M | $5.71M | $1.67M |
High Forecast | $25.53M | $27.44M | $29.48M | $31.68M | $6.63M | $7.09M | $1.63M | $1.92M | $5.71M | $1.67M |
Low Forecast | $25.53M | $27.44M | $29.48M | $31.68M | $6.63M | $7.09M | $1.63M | $1.92M | $5.71M | $1.67M |
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 |
Surprise % | - | - | - | - | - | - | - | - | - | - |
Prime Medicine EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | $-51.46M |
Avg Forecast | $15.32M | $16.46M | $17.69M | $19.01M | $3.98M | $4.25M | $978.00K | $1.15M | $3.43M | $1.00M |
High Forecast | $15.32M | $16.46M | $17.69M | $19.01M | $3.98M | $4.25M | $978.00K | $1.15M | $3.43M | $1.00M |
Low Forecast | $15.32M | $16.46M | $17.69M | $19.01M | $3.98M | $4.25M | $978.00K | $1.15M | $3.43M | $1.00M |
Surprise % | - | - | - | - | - | - | - | - | - | -51.46% |
Prime Medicine Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 |
Net Income | - | - | - | - | - | - | - | - | - | $-50.71M |
Avg Forecast | $-39.69M | $-39.07M | $-45.68M | $-47.42M | $-45.72M | $-45.93M | $-46.46M | $-54.22M | $-66.27M | $-51.75M |
High Forecast | $-39.69M | $-39.07M | $-45.68M | $-47.42M | $-45.72M | $-37.38M | $-46.46M | $-54.22M | $-60.74M | $-51.75M |
Low Forecast | $-39.69M | $-39.07M | $-45.68M | $-47.42M | $-45.72M | $-50.20M | $-46.46M | $-54.22M | $-73.17M | $-51.75M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.98% |
Prime Medicine SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 |
SG&A | - | - | - | - | - | - | - | - | - | $10.49M |
Avg Forecast | $23.53M | $25.28M | $27.17M | $29.19M | $6.11M | $6.53M | $1.50M | $1.77M | $5.27M | $1.54M |
High Forecast | $23.53M | $25.28M | $27.17M | $29.19M | $6.11M | $6.53M | $1.50M | $1.77M | $5.27M | $1.54M |
Low Forecast | $23.53M | $25.28M | $27.17M | $29.19M | $6.11M | $6.53M | $1.50M | $1.77M | $5.26M | $1.54M |
Surprise % | - | - | - | - | - | - | - | - | - | 6.83% |
Prime Medicine EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 |
EPS | - | - | - | - | - | - | - | - | - | $-0.55 |
Avg Forecast | $-0.33 | $-0.33 | $-0.38 | $-0.40 | $-0.38 | $-0.39 | $-0.39 | $-0.45 | $-0.56 | $-0.43 |
High Forecast | $-0.33 | $-0.33 | $-0.38 | $-0.40 | $-0.38 | $-0.31 | $-0.39 | $-0.45 | $-0.51 | $-0.43 |
Low Forecast | $-0.33 | $-0.33 | $-0.38 | $-0.40 | $-0.38 | $-0.42 | $-0.39 | $-0.45 | $-0.61 | $-0.43 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.27% |
Prime Medicine Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
NTLA | Intellia Therapeutics | $15.14 | $118.84 | 684.94% | Buy |
LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
EDIT | Editas Medicine | $2.88 | $13.50 | 368.75% | Buy |
PRME | Prime Medicine | $3.96 | $17.25 | 335.61% | Buy |
VERV | Verve Therapeutics | $6.05 | $21.50 | 255.37% | Buy |
RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
BEAM | Beam Therapeutics | $24.36 | $64.20 | 163.55% | Buy |
CRSP | CRISPR Therapeutics | $50.59 | $109.58 | 116.60% | Buy |
RPRX | Royalty Pharma | $27.20 | $43.33 | 59.30% | Buy |
CRBU | Caribou Biosciences | $2.34 | $3.00 | 28.21% | Buy |
BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
RPHM | Reneo Pharmaceuticals | $18.20 | $18.00 | -1.10% | Buy |
DNA | Ginkgo Bioworks | $7.63 | $7.34 | -3.80% | Buy |
PRME Forecast FAQ
Is Prime Medicine a good buy?
Yes, according to 6 Wall Street analysts, Prime Medicine (PRME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of PRME's total ratings.
What is PRME's price target?
Prime Medicine (PRME) average price target is $17.25 with a range of $12 to $23, implying a 335.61% from its last price of $3.96. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Prime Medicine stock go up soon?
According to Wall Street analysts' prediction for PRME stock, the company can go up by 335.61% (from the last price of $3.96 to the average price target of $17.25), up by 480.81% based on the highest stock price target, and up by 203.03% based on the lowest stock price target.
Can Prime Medicine stock reach $6?
PRME's average twelve months analyst stock price target of $17.25 supports the claim that Prime Medicine can reach $6 in the near future.
What are Prime Medicine's analysts' financial forecasts?
Prime Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $17.27M (high $17.27M, low $17.27M), average EBITDA is $10.36M (high $10.36M, low $10.36M), average net income is $-192M (high $-184M, low $-197M), average SG&A $15.91M (high $15.91M, low $15.91M), and average EPS is $-1.614 (high $-1.542, low $-1.649). PRME's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $114.14M (high $114.14M, low $114.14M), average EBITDA is $68.48M (high $68.48M, low $68.48M), average net income is $-172M (high $-172M, low $-172M), average SG&A $105.17M (high $105.17M, low $105.17M), and average EPS is $-1.442 (high $-1.442, low $-1.442).